Under a tenth of people that would benefit from obesity jabs including Wegovy are able to get them, states the WHO as it releases its inaugural guidance on the medications.
Given more than one billion individuals worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be addressed with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key barriers to widespread access to the treatments that can aid individuals in losing substantial body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Even under the present best projected case, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, as stated by the WHO.
The guideline urges nations and manufacturers to increase availability, through strategies including voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Function
These medications mimick a biological compound to reduce digestion speed, suppress the appetite and increase satiety so people consume fewer calories.
Patients commonly start to lose weight after several weeks of commencing the regular doses.
Research suggests users may see weight return within a year of discontinuing the treatment, because their typical hunger return.
To be above a healthy weight raises your risk for contracting health problems, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
